BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 19318232)

  • 1. High CD49d protein and mRNA expression predicts poor outcome in chronic lymphocytic leukemia.
    Nückel H; Switala M; Collins CH; Sellmann L; Grosse-Wilde H; Dührsen U; Rebmann V
    Clin Immunol; 2009 Jun; 131(3):472-80. PubMed ID: 19318232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A scoring system based on the expression of six surface molecules allows the identification of three prognostic risk groups in B-cell chronic lymphocytic leukemia.
    Zucchetto A; Bomben R; Dal Bo M; Sonego P; Nanni P; Rupolo M; Bulian P; Dal Maso L; Del Poeta G; Del Principe MI; Degan M; Gattei V
    J Cell Physiol; 2006 May; 207(2):354-63. PubMed ID: 16331666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ZAP-70 protein expression and CD38 positivity in B-cell chronic lymphocytic leukemia.
    Ertault-Daneshpouy M; Noguera ME; Gisselbrecht C; Haddad A; Brice P; Marolleau JP; Soulier J; Mounier N
    Clin Adv Hematol Oncol; 2008 Jan; 6(1):55-63. PubMed ID: 18322442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T-cell CD38 expression in B-chronic lymphocytic leukaemia.
    Abousamra NK; El-Din MS; Azmy E
    Hematol Oncol; 2009 Jun; 27(2):82-9. PubMed ID: 19247976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Zeta-chain associated protein 70 and CD38 combined predict the time to first treatment in patients with chronic lymphocytic leukemia.
    Del Giudice I; Morilla A; Osuji N; Matutes E; Morilla R; Burford A; Maravelaki S; Owusu-Ankomah K; Swansbury J; A'Hern R; Brito-Babapulle V; Catovsky D
    Cancer; 2005 Nov; 104(10):2124-32. PubMed ID: 16211545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FCRL2 mRNA expression is inversely associated with clinical progression in chronic lymphocytic leukemia.
    Nückel H; Collins CH; Frey UH; Sellmann L; Dürig J; Siffert W; Dührsen U
    Eur J Haematol; 2009 Dec; 83(6):541-9. PubMed ID: 19682311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of combined analysis of ZAP-70 and CD38 in chronic lymphocytic leukemia.
    D'Arena G; Tarnani M; Rumi C; Vaisitti T; Aydin S; De Filippi R; Perrone F; Pinto A; Chiusolo P; Deaglio S; Malavasi F; Laurenti L
    Am J Hematol; 2007 Sep; 82(9):787-91. PubMed ID: 17534928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD38/CD31, the CCL3 and CCL4 chemokines, and CD49d/vascular cell adhesion molecule-1 are interchained by sequential events sustaining chronic lymphocytic leukemia cell survival.
    Zucchetto A; Benedetti D; Tripodo C; Bomben R; Dal Bo M; Marconi D; Bossi F; Lorenzon D; Degan M; Rossi FM; Rossi D; Bulian P; Franco V; Del Poeta G; Deaglio S; Gaidano G; Tedesco F; Malavasi F; Gattei V
    Cancer Res; 2009 May; 69(9):4001-9. PubMed ID: 19383907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical relevance of the expression of the CD31 ligand for CD38 in patients with B-cell chronic lymphocytic leukemia.
    Ibrahim S; Jilani I; O'Brien S; Rogers A; Manshouri T; Giles F; Faderl S; Thomas D; Kantarjian H; Keating M; Albitar M
    Cancer; 2003 Apr; 97(8):1914-9. PubMed ID: 12673718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Zap-70 and CD38 as predictors of IgVH mutation in CLL.
    Cruse JM; Lewis RE; Webb RN; Sanders CM; Suggs JL
    Exp Mol Pathol; 2007 Dec; 83(3):459-61. PubMed ID: 17931624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD49d and CD26 are independent prognostic markers for disease progression in patients with chronic lymphocytic leukemia.
    Ibrahem L; Elderiny WE; Elhelw L; Ismail M
    Blood Cells Mol Dis; 2015 Aug; 55(2):154-60. PubMed ID: 26142332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rel a is an independent biomarker of clinical outcome in chronic lymphocytic leukemia.
    Hewamana S; Lin TT; Rowntree C; Karunanithi K; Pratt G; Hills R; Fegan C; Brennan P; Pepper C
    J Clin Oncol; 2009 Feb; 27(5):763-9. PubMed ID: 19124804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD49d expression is an independent risk factor of progressive disease in early stage chronic lymphocytic leukemia.
    Rossi D; Zucchetto A; Rossi FM; Capello D; Cerri M; Deambrogi C; Cresta S; Rasi S; De Paoli L; Bodoni CL; Bulian P; Del Poeta G; Ladetto M; Gattei V; Gaidano G
    Haematologica; 2008 Oct; 93(10):1575-9. PubMed ID: 18641015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical utility of molecular and flow cytometric markers in chronic lymphocytic leukaemia.
    Sulda ML; Kuss BJ; Hall RK; Bailey S; Macardle PJ
    Intern Med J; 2012 Feb; 42(2):137-46. PubMed ID: 20561095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication.
    Bosch F; Ferrer A; Villamor N; González M; Briones J; González-Barca E; Abella E; Gardella S; Escoda L; Pérez-Ceballos E; Asensi A; Sayas MJ; Font L; Altés A; Muntañola A; Bertazzoni P; Rozman M; Aymerich M; Giné E; Montserrat E
    Clin Cancer Res; 2008 Jan; 14(1):155-61. PubMed ID: 18172266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surface-antigen expression profiling (SEP) in B-cell chronic lymphocytic leukemia (B-CLL): Identification of markers with prognostic relevance.
    Zucchetto A; Sonego P; Degan M; Bomben R; Dal Bo M; Russo S; Attadia V; Rupolo M; Buccisano F; Steffan A; Del Poeta G; Pucillo C; Colombatti A; Campanini R; Gattei V
    J Immunol Methods; 2005 Oct; 305(1):20-32. PubMed ID: 16198366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Feasibility of an easily applicable method of ZAP-70 measurement in chronic lymphocytic leukemia in the routine flow cytometry setting: A methodological approach.
    Passam F; Tachynopoulou V; Skoumi D; Tsompanakou A; Stavropoulos-Giokas A; Vadikolia C; Anagnostopoulos A; Paterakis G
    Ann Hematol; 2006 Nov; 85(11):795-805. PubMed ID: 16871389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD26 expression in mature B-cell neoplasia: its possible role as a new prognostic marker in B-CLL.
    Cro L; Morabito F; Zucal N; Fabris S; Lionetti M; Cutrona G; Rossi F; Gentile M; Ferrario A; Ferrarini M; Molica S; Neri A; Baldini L
    Hematol Oncol; 2009 Sep; 27(3):140-7. PubMed ID: 19247978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD31 density is a novel risk factor for patients with B-cell chronic lymphocytic leukaemia.
    Mainou-Fowler T; Porteous A; Nicolle A; Proctor SJ; Anderson JJ; Summerfield G
    Int J Oncol; 2008 Jul; 33(1):169-74. PubMed ID: 18575763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High intracellular content of cyclin-dependent kinase inhibitor p27(Kip1) in early- and intermediate stage B-cell chronic lymphocytic leukemia lymphocytes predicts rapid progression of the disease.
    Wolowiec D; Wojtowicz M; Ciszak L; Kosmaczewska A; Frydecka I; Potoczek S; Urbaniak-Kujda D; Kapelko-Slowik K; Kuliczkowski K
    Eur J Haematol; 2009 Apr; 82(4):260-6. PubMed ID: 19187271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.